The global Left Atrial Appendage Occluder market size is projected to grow from USD 12.7 billion in 2023 to USD 49.4 Billion by 2029

Left Atrial Appendage Occluder Market Summary

The left atrial appendage is the forward protruding part of the right front of the left atrium and is a tissue structure closely related to atrial fibrillation. The thrombus formed in the left atrial appendage is easy to fall off, and will move with the blood flow to the brain, kidneys and other parts to form embolism, which has a high disability and mortality rate. Left atrial appendage occlusion is to fix the occluder in the left atrial appendage to prevent the thrombus that may form in the left atrial appendage from falling off during atrial fibrillation. The left atrial appendage occlusion device is a medical device used in left atrial appendage occlusion surgery for patients with atrial fibrillation.

According to the new market research report "Global Left Atrial Appendage Occluder Market Report 2023-2029", published by GIResearch, the global Left Atrial Appendage Occluder market size is projected to grow from USD 12.7 billion in 2023 to USD 49.4 Billion by 2029, at a CAGR of 21.4% during the forecast period.

• Global Left Atrial Appendage Occluder MarketSize(US$ Billion), 2018-2029

Source: GlobalInfoResearch, “Global Left Atrial Appendage Occluder Market 2024 by Company, Regions, Type and Application, Forecast to 2030”

• Global Left Atrial Appendage Occluder Top9Players Ranking and Market Share（Continually updated）

Source: GlobalInfoResearch, “Global Left Atrial Appendage Occluder Market 2024 by Company, Regions, Type and Application, Forecast to 2030”

Globally, major manufacturers of left atrial appendage occlusion devices include Boston Scientific, Abbott, Occlutech, Atircure, J&J, etc., with the top five manufacturers accounting for approximately 95.94% of the market share.

Since the left atrial appendage occluder has a specific location and morphological characteristics, there are extremely high requirements for its development and production. It was not until 2002 that the first left atrial appendage occluding device "PLATO" appeared on the global market. Unfortunately, the development of this occluding device was later terminated due to complications and funding issues. The company that has truly realized the global promotion and application of left atrial appendage occlusion devices is Boston Scientific, whose WATCHMAN left atrial appendage occlusion device is now the “gold standard” of left atrial appendage occlusion devices. In 2006, the WATCHMAN left atrial appendage occlusion device obtained CE certification and entered the European market; in 2009, Europe and Australia took the lead in carrying out WATCHMAN left atrial appendage occlusion treatment, with Germany having an annual implantation volume of up to 3,000 cases; the United States started late, in March 2015 The WATCHMAN left atrial appendage occlusion device has just been approved by the FDA, and currently the number of implants annually reaches over 10,000.

Major left atrial appendage occlusion device companies include:

Boston Scientific: Boston Scientific is the world's leading medical device company. Its Watchman® left atrial appendage occlusion device is the world's first approved left atrial appendage occlusion device, which has the advantages of high safety and strong effectiveness.

Abbott: Abbott is the world's leading healthcare company. Its Amulet® left atrial appendage occlusion device is the world's first fully recyclable and releasable left atrial appendage occlusion device. It has the advantages of high flexibility and adaptability.

Occlutech: Occlutech is a leading provider of minimally invasive cardiac implants for the treatment of structural heart disease. Founded in 2003, the company is headquartered in Istanbul, Turkey, with manufacturing facilities in Germany and Switzerland. Occlutech® occluders are made of self-expanding nitinol mesh covered with a thin biocompatible fabric. It is inserted through a catheter inserted into a blood vessel (usually in the groin) and placed over the opening of the left atrial appendage. The nitinol mesh expands to fit the shape of the left atrial appendage, and the fabric seals the opening, preventing blood clots from forming inside.

AtriCure: AtriCure is a medical device company developing innovative technologies to treat atrial fibrillation (AFib) and related conditions. Founded in 1997, the company has become a global leader in its field, delivering solutions that improve the lives of patients around the world. Its AtriClip® left atrial appendage occlusion device is the world's first transfemoral vein transcatheter implantable left atrial appendage occlusion device.

Contact Us:

If you have any questions or have further requirements about this report, please contact us.

GlobaI Info Research Co.,Ltd

Website: https://www.globalinforesearch.com

TEL: CN: 0086-176 6505 2062

TEL: HK: 00852-58030175

TEL: US: 001-347 966 1888

E-mail: report@globalinforesearch.com

About Global Info Research:

Global Info Research is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.

Global Info Research has more than 30000 global well-known customers, covering more than 30 industries, research regions cover China,Japan,Korea,US,EU,Asia,Middle East and Africa,South America,Australia,etc.